Zeltia Overview

  • Year Founded
  • 1939

Year Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

  • Financing Rounds
  • 2

  • Investments
  • 3

Zeltia General Information

Description

Operator of a biopharmaceutical company dedicated to exploring the marine universe in search of innovative treatments. The company is carrying out a pioneering program in marine biotechnology for the discovery of new medicines of marine origin with antitumor activity for oncology, central nervous system, molecular diagnostics, and genetic identification and RNAi (RNA interference) illness treatments.

Contact Information

Website
www.zeltia.com
Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • Plaza del Descubridor Diego de Ordás
  • 3, planta 5
  • 28003 Madrid
  • Spain
Primary Industry
Biotechnology
Vertical(s)
Corporate Office
  • Plaza del Descubridor Diego de Ordás
  • 3, planta 5
  • 28003 Madrid
  • Spain

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Zeltia Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Zeltia‘s full profile, request access.

Request a free trial

Zeltia Patents

Zeltia Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-2213286-A1 N-(phenyl or pyridyl)prenylamine derivatives for the treatment of obesity, diabetes and cardiovascular diseases Inactive 02-Feb-2009
WO-2010086454-A1 N-(phenyl or pyridyl)prenylamine derivatives for the treatment of obesity, diabetes, cardiovascular diseases and other adiponectin-related diseases Inactive 02-Feb-2009
WO-2010086454-A9 N-(phenyl or pyridyl)prenylamine derivatives for the treatment of obesity, diabetes, cardiovascular diseases and other adiponectin-related diseases Inactive 02-Feb-2009
EP-2020447-A1 Method for identifying compounds modulating adiponectin gene expression Inactive 03-Aug-2007
WO-2009019208-A1 Method for identifying compounds modulating adiponectin gene expression Inactive 03-Aug-2007 C12Q1/6883
To view Zeltia’s complete patent history, request access »

Zeltia Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Zeltia‘s full profile, request access.

Request a free trial

Zeltia Investments & Acquisitions (3)

Zeltia’s most recent deal was a Reverse Merger with Pharma Mar. The deal was made on 02-Nov-2014.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Pharma Mar 02-Nov-2014 Reverse Merger Other Pharmaceuticals and Biotechnology
Xylazel 01-Jan-1999 Merger/Acquisition Specialty Chemicals
Xylazel 01-Jan-1975 Joint Venture Specialty Chemicals
To view Zeltia’s complete investments and acquisitions history, request access »

Zeltia Exits (2)

Zeltia’s most recent exit was on 01-Jan-1999 from Xylazel. The exit was categorized as .

Company Name Exit Date Exit Type Exit Size Status Buyers
Xylazel 01-Jan-1999 Completed
Xylazel 01-Jan-1975 Joint Venture Completed
  • 2 buyers
To view Zeltia’s complete exits history, request access »

Zeltia FAQs

  • When was Zeltia founded?

    Zeltia was founded in 1939.

  • Where is Zeltia headquartered?

    Zeltia is headquartered in Madrid, Spain.

  • What industry is Zeltia in?

    Zeltia’s primary industry is Biotechnology.

  • Is Zeltia a private or public company?

    Zeltia is a Private company.

  • What is Zeltia’s current revenue?

    The current revenue for Zeltia is .

  • Who are Zeltia’s investors?

    Pharma Mar has invested in Zeltia.

  • When was Zeltia acquired?

    Zeltia was acquired on 02-Nov-2014.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process